| Primary |
| Product Used For Unknown Indication |
30.9% |
| Drug Use For Unknown Indication |
10.3% |
| Pneumonia |
10.2% |
| Bronchitis |
6.5% |
| Urinary Tract Infection |
5.4% |
| Hypertension |
4.9% |
| Sinusitis |
4.6% |
| Pulmonary Tuberculosis |
3.2% |
| Tuberculosis |
2.8% |
| Infection |
2.8% |
| Pyrexia |
2.6% |
| Prophylaxis |
2.3% |
| Atrial Fibrillation |
2.0% |
| Cystitis |
1.9% |
| Respiratory Tract Infection |
1.9% |
| Chronic Obstructive Pulmonary Disease |
1.8% |
| Nasopharyngitis |
1.6% |
| Diabetes Mellitus |
1.5% |
| Ill-defined Disorder |
1.4% |
| Cardiac Failure |
1.4% |
|
| Tendonitis |
11.2% |
| Tendon Rupture |
10.6% |
| Vomiting |
8.8% |
| Pain In Extremity |
7.9% |
| Tendon Pain |
6.9% |
| Urticaria |
5.8% |
| Rash |
4.9% |
| Tendon Disorder |
4.9% |
| Tremor |
4.1% |
| Pruritus |
3.9% |
| Myalgia |
3.6% |
| Delirium |
3.5% |
| Renal Failure Acute |
3.5% |
| Interstitial Lung Disease |
3.3% |
| Pain |
3.3% |
| Drug Interaction |
3.1% |
| Hypoglycaemia |
2.8% |
| Loss Of Consciousness |
2.8% |
| Arthralgia |
2.6% |
| Pneumonia |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
29.7% |
| Drug Use For Unknown Indication |
9.3% |
| Hypertension |
8.5% |
| Pneumonia |
7.0% |
| Pyrexia |
4.6% |
| Pulmonary Tuberculosis |
4.5% |
| Urinary Tract Infection |
4.0% |
| Asthma |
3.9% |
| Chronic Obstructive Pulmonary Disease |
3.1% |
| Infection |
3.1% |
| Bacteraemia |
2.7% |
| Prophylaxis |
2.6% |
| Antibiotic Prophylaxis |
2.5% |
| Bronchitis |
2.3% |
| Respiratory Tract Infection |
2.3% |
| Type 2 Diabetes Mellitus |
2.3% |
| Rheumatoid Arthritis |
2.2% |
| Sepsis |
1.9% |
| Tuberculosis |
1.8% |
| Pain |
1.8% |
|
| Toxic Epidermal Necrolysis |
10.6% |
| Tendonitis |
10.3% |
| Renal Failure Acute |
6.7% |
| Tendon Rupture |
6.7% |
| Pyrexia |
6.3% |
| Interstitial Lung Disease |
5.8% |
| Myocardial Infarction |
5.0% |
| Vomiting |
5.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.9% |
| Drug Interaction |
4.3% |
| Urosepsis |
4.3% |
| White Blood Cell Count Increased |
3.8% |
| Tenosynovitis Stenosans |
3.6% |
| White Blood Cell Count Decreased |
3.6% |
| Pneumonia |
3.4% |
| Drug Eruption |
3.2% |
| Thrombocytopenia |
3.2% |
| Malaise |
3.1% |
| Rash |
3.1% |
| Septic Shock |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.1% |
| Drug Use For Unknown Indication |
17.8% |
| Prophylaxis |
11.9% |
| Infection Prophylaxis |
5.0% |
| Hypertension |
3.8% |
| Multiple Myeloma |
3.6% |
| Pain |
3.5% |
| Aplastic Anaemia |
3.0% |
| Premedication |
2.9% |
| Constipation |
2.5% |
| Acute Myeloid Leukaemia |
2.5% |
| Pneumonia |
2.5% |
| Rheumatoid Arthritis |
2.0% |
| Antifungal Prophylaxis |
1.8% |
| Insomnia |
1.8% |
| Prophylaxis Against Graft Versus Host Disease |
1.8% |
| Pyrexia |
1.7% |
| Nausea |
1.6% |
| Diabetes Mellitus |
1.6% |
| Bone Marrow Conditioning Regimen |
1.5% |
|
| Pneumonia |
10.4% |
| Pyrexia |
10.3% |
| White Blood Cell Count Decreased |
10.2% |
| Vomiting |
8.8% |
| Thrombocytopenia |
7.9% |
| Sepsis |
5.9% |
| Febrile Neutropenia |
4.8% |
| Renal Failure Acute |
4.2% |
| Death |
4.1% |
| Urinary Tract Infection |
3.6% |
| Respiratory Failure |
3.5% |
| Weight Decreased |
3.2% |
| Renal Failure |
3.2% |
| Pulmonary Embolism |
3.1% |
| Interstitial Lung Disease |
3.0% |
| Neutropenia |
3.0% |
| Weight Increased |
3.0% |
| Rash |
2.7% |
| Platelet Count Decreased |
2.6% |
| Septic Shock |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
32.6% |
| Drug Use For Unknown Indication |
7.6% |
| Urinary Tract Infection |
7.6% |
| Hypertension |
6.9% |
| Atrial Fibrillation |
5.5% |
| Ischaemic Heart Disease Prophylaxis |
4.1% |
| Pneumonia |
4.1% |
| Dysphagia |
3.8% |
| Helicobacter Infection |
3.4% |
| Type 2 Diabetes Mellitus |
3.4% |
| Unevaluable Event |
2.7% |
| Asthma |
2.4% |
| Infection |
2.4% |
| Pain |
2.4% |
| Acute Promyelocytic Leukaemia |
2.1% |
| Cardiac Failure |
2.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.1% |
| Pyrexia |
2.1% |
| Bacterial Infection |
1.4% |
| Upper Respiratory Tract Infection |
1.4% |
|
| Drug Interaction |
42.9% |
| Status Epilepticus |
7.1% |
| Hypoglycaemia |
5.4% |
| Respiratory Tract Infection |
5.4% |
| Hypoglycaemic Coma |
3.6% |
| International Normalised Ratio Increased |
3.6% |
| Loss Of Consciousness |
3.6% |
| Myositis |
3.6% |
| Pericardial Haemorrhage |
3.6% |
| Staphylococcal Infection |
3.6% |
| Blood Glucose Increased |
1.8% |
| Convulsion |
1.8% |
| Electrocardiogram Qt Interval Abnormal |
1.8% |
| Electrocardiogram Qt Prolonged |
1.8% |
| Electrocardiogram T Wave Amplitude Decreased |
1.8% |
| Gastrointestinal Haemorrhage |
1.8% |
| Haemorrhage |
1.8% |
| Hypocoagulable State |
1.8% |
| Nasopharyngitis |
1.8% |
| Pneumonia |
1.8% |
|
